Checkmate Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Checkmate Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11018
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:23
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Checkmate Pharmaceuticals Inc (Checkmate Pharmaceuticals) is a clinical stage company that discovers and develops immunotherapies to provide new treatment options for patients and the healthcare providers. The company’s lead product candidate, CMP-001, is a CpG oligonucleotides (CpG-A ODN) that converts immunologically cold tumors to immunologically hot tumors. It also evaluates CMP-001-001, an open label study of intratumoral administration of CMP-001 in combination with pembrolizumab in patients with advanced cutaneous melanoma. Checkmate Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.

Checkmate Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Checkmate Pharma Raises USD27 Million in Series B Preferred Financing 10
Checkmate Pharma Raises Additional USD5 Million in Venture Financing 11
Checkmate Pharmaceuticals Raises USD20 Million in Series A Round of Financing 12
Partnerships 13
Checkmate Pharma Enters into Partnership with Merck and Pfizer 13
Biodesix Enters into Research Agreement with Checkmate Pharma 14
Genocea Biosciences Enters into Research Agreement with Checkmate Pharma 15
Licensing Agreements 16
Checkmate Pharma Amends Licensing Agreement with Kuros Biosciences 16
Checkmate Pharmaceuticals Inc – Key Competitors 17
Checkmate Pharmaceuticals Inc – Key Employees 18
Checkmate Pharmaceuticals Inc – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Clinical Trials 20
Apr 24, 2018: Checkmate Pharmaceuticals Announces Start of Phase 1b Trial of CMP-001 in Combination with Anti-PD-L1 Immunotherapy in Anti-PD-1/PD-L1 Resistant Advanced Non-Small Cell Lung Cancer 20
Apr 17, 2018: Checkmate Pharmaceuticals Presents Clinical Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting 21
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23

List of Tables
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Checkmate Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Checkmate Pharma Raises USD27 Million in Series B Preferred Financing 10
Checkmate Pharma Raises Additional USD5 Million in Venture Financing 11
Checkmate Pharmaceuticals Raises USD20 Million in Series A Round of Financing 12
Checkmate Pharma Enters into Partnership with Merck and Pfizer 13
Biodesix Enters into Research Agreement with Checkmate Pharma 14
Genocea Biosciences Enters into Research Agreement with Checkmate Pharma 15
Checkmate Pharma Amends Licensing Agreement with Kuros Biosciences 16
Checkmate Pharmaceuticals Inc, Key Competitors 17
Checkmate Pharmaceuticals Inc, Key Employees 18

List of Figures
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Checkmate Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Checkmate Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Incanthera Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Incanthera Ltd (Incanthera) is a drug development and targeted cancer medicines company that discovers and develops novel treatments for solid tumours. The company's pipeline drug candidates include ICT01-2588, a vascular disrupting agent, based on the tumor-blasting technology; ICT03 – Es5, …
  • Famous Dave’s of America, Inc.:企業の戦略・SWOT・財務情報
    Famous Dave's of America, Inc. - Strategy, SWOT and Corporate Finance Report Summary Famous Dave's of America, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Medicago Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Medicago Inc (Medicago), a subsidiary of Mitsubishi Tanabe Pharma Corp is a clinical-stage biotechnology company that develops and produces vaccines and antibodies. The company concentrates on the discovery and development of novel vaccines and therapeutic proteins for infectious diseases. I …
  • Aratana Therapeutics Inc (PETX):企業の財務・戦略的SWOT分析
    Summary Aratana Therapeutics Inc (Aratana) is a provider of pet care solutions. The company develops, commercializing and markets biopharmaceutical products for medical condition in cats and dogs. Its pipeline portfolio consists of small molecule pharmaceuticals and large molecule biologics that aim …
  • Grupo Financiero Galicia S.A. (GGAL3):企業の財務・戦略的SWOT分析
    Grupo Financiero Galicia S.A. (GGAL3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • ACWA Power International:企業の戦略的SWOT分析
    ACWA Power International - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Subsea 7 SA (SUBC):電力:M&Aディール及び事業提携情報
    Summary Subsea 7 SA (Subsea 7) is a contractor in seabed-to-surface engineering, construction and services. The company provides engineering, project management, supply chain, and vessel management services. It connects seabed wellhead structures to surface facilities, such as platforms and floating …
  • Plains All American Pipeline LP (PAA):企業の財務・戦略的SWOT分析
    Plains All American Pipeline LP (PAA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Ohr Pharmaceutical Inc (OHRP):企業の財務・戦略的SWOT分析
    Summary Ohr Pharmaceutical Inc (Ohr), formerly BBM Holdings Inc, is a pharmaceutical company that develops novel therapies for ophthalmic diseases. The company offers products such as squalamine lactate ophthalmic solution and SKS sustained release technology products. Its squalamine lactate ophthal …
  • Nippon Suisan Kaisha, Ltd.:企業の戦略・SWOT・財務情報
    Nippon Suisan Kaisha, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nippon Suisan Kaisha, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Titan Logix Corp (TLA):企業の財務・戦略的SWOT分析
    Summary Titan Logix Corp (Titan) is a technology company that offers research and development, manufacturing and marketing of advanced technology fluid management solutions. The company's products include stationary guided wave radar gauges for level measurement and overfill prevention, for use in t …
  • Advanced Marker Discovery SL-医療機器分野:企業M&A・提携分析
    Summary Advanced Marker Discovery SL (Amadix) is a developer and discoverer of cancer diagnostic products. The company offers test products and diagnostic tools for lung cancer, colon cancer and prostate cancer. It provides diagnostic tools that support the physician’s decisions about patient manage …
  • Oxtex Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Oxtex Ltd (Oxtex), formerly Oxtexs Ltd is a medical device company that offers novel self inflating tissue expansion and medical devices. The company’s products include implantable self-inflating tissue expanders that are suitable for specific needs of the clinician and the patient. It uses …
  • Petroleos de Venezuela SA:石油・ガス:M&Aディール及び事業提携情報
    Summary Petroleos de Venezuela SA (PDVSA) is a state-owned oil and gas company. It plans, coordinates, supervises, and controls the activities in the entire oil and gas value chain. The company explores for and develops oil and other hydrocarbons; refines, trades, and supplies that in domestic and o …
  • Korea Aerospace Industries Ltd:企業の戦略・SWOT・財務分析
    Korea Aerospace Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Korea Aerospace Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Duke Energy Carolinas LLC:企業の戦略的SWOT分析
    Duke Energy Carolinas LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Meridiana fly SpA:企業の戦略・SWOT・財務情報
    Meridiana fly SpA - Strategy, SWOT and Corporate Finance Report Summary Meridiana fly SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Consolis SAS:企業の戦略・SWOT・財務情報
    Consolis SAS - Strategy, SWOT and Corporate Finance Report Summary Consolis SAS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • PT Tiphone Mobile Indonesia Tbk (TELE):企業の財務・戦略的SWOT分析
    PT Tiphone Mobile Indonesia Tbk (TELE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Zhuhai Holdings Investment Group Co Ltd
    Zhuhai Holdings Investment Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Zhuhai Holdings Investment Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆